ENB-255

ENB-255 is a preclinical-stage small molecule drug candidate being developed by Engine Biosciences for the treatment of triple-negative breast cancer (TNBC). Discovered using Engine's proprietary NetMAP and REVEAL platforms—which integrate high-throughput CRISPR screening with machine learning to map gene-gene interactions—ENB-255 is designed to exploit a specific synthetic lethal vulnerability within TNBC cells. The program is part of Engine's precision oncology strategy, which focuses on identifying novel first-in-class targets and corresponding predictive biomarkers to select patient populations most likely to respond to therapy. While the specific molecular target of ENB-255 remains proprietary and has not been publicly disclosed, the program aims to address the high unmet medical need in TNBC through a precision medicine approach.